Vident Investment Advisory, LLC Incyte Corp Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $1.5 Million - $1.83 Million	-21,299 Reduced 54.07%	18,090 $1.31 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $1.41 Million - $1.77 Million	21,041 Added 114.68%	39,389 $3.16 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $1.03 Million - $1.29 Million	15,595 Added 566.47%	18,348 $1.21 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $339,768 - $427,046	-5,134 Reduced 65.09%	2,753 $209,000
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $520,699 - $628,672	7,887 New	7,887 $626,000
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $379,659 - $444,215	-5,994 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $17,854 - $21,845	260 Added 4.53%	5,994 $412,000
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $23,721 - $25,996	-297 Reduced 4.92%	5,734 $482,000
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $46,980 - $62,109	618 Added 11.42%	6,031 $490,000
Q4 2020 Feb 08, 2021	BUY	$80.74 - $97.7 $30,842 - $37,321	382 Added 7.59%	5,413 $471,000
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $860,568 - $1.11 Million	-10,116 Reduced 66.79%	5,031 $451,000
Q2 2020 Jul 17, 2020	BUY	$74.18 - $108.93 $1.12 Million - $1.65 Million	15,147 New	15,147 $1.57 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $1.27 Million - $1.75 Million	-20,821 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $237,883 - $289,206	2,864 Added 15.95%	20,821 $1.47 Million
Q4 2017 Feb 15, 2018	BUY	$93.56 - $116.6 $767,659 - $956,703	8,205 Added 84.14%	17,957 $1.99 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $1.06 Million - $1.35 Million	9,752	9,752 $1.32 Million

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account